Metraipolis › archive › dc_50c8a2bd5785
Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:41973722
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41973722
- DOI
- 10.1371/journal.pone.0346797
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T00:52:36.435Z
- SHA-256 of the archived text
edc5b17174edb3648ea288d818f1bbd38d437c87d257ead4f5144037e936572b- Stable URL of this page
https://metraipolis.com/documento/dc_50c8a2bd5785
How to cite
Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:41973722 — Europe PMC (en), https://europepmc.org/article/MED/41973722 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_50c8a2bd5785 (Metraipolis archive dc_50c8a2bd5785, sha256 edc5b17174edb3648ea288d818f1bbd38d437c87d257ead4f5144037e936572b)
BibTeX
@misc{dc50c8a2bd5785,
title = {Adverse events in different administration routes of Edaravone: A pharmacovigilance study based on the FDA adverse event reporting system — Europe PMC PMID:41973722},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41973722},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_50c8a2bd5785; sha256 edc5b17174edb3648ea288d818f1bbd38d437c87d257ead4f5144037e936572b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41973722. Agents can read the archived copy with the MCP tool read_document.